Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
KLRA
Strong SellSinkerKailera Therapeutics, Inc. · Healthcare · United States · $2.1B · Avg Vol: $9M/d
11
StockRankGet insider-trade alerts
Q
35
V
31
M
21
P/E (TTM)
—
ROE
—
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions.
FINANCIAL SUMMARY (USD)
| Year | 2024 | 2025 | TTM |
|---|---|---|---|
| Revenue | — | 0 | — |
| EPS | — | -1.26 | -2.25 |
| Shares | 117.9M | 117.9M | 129.6M |
| Debt | 0.5M | 10.8M | 10.2M |
| Equity | -218.8M | -356.5M | — |
| Op CF | — | -120.2M | -221.6M |
| Inv CF | — | -492.6M | — |
| Fin CF | — | 598.7M | — |
Loading 1Y...
PRICE (1Y)-12.1%
SMA 50SMA 200
Close
$14.84
RSI (14)
34.0
SCORE BREAKDOWN
Quality
35
ROIC
-24.5%27.4
ROE
—N/A
GP/Assets
—N/A
Op. Margin
0.0%38.1
FCF/Assets
-17.7%22.9
Piotroski
219.8
Int. Cover
—N/A
D/E Ratio
0.01x85.1
Current Ratio
11.11x88.9
Value
31
P/E (TTM)
—N/A
EV/EBITDA
-3.6x25.0
P/FCF
—N/A
P/B
1.9x65.3
P/S
—N/A
Div Yield
—N/A
Momentum
21
52W High %
—N/A
RS 6M
—N/A
SMA 50/200
—N/A
EPS Rev 4W
-4.9%13.7
EPS Rev 12W
—N/A
EPS Improve
-91%5.9
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$2.1B
P/E (Forward)
-3.8x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of KLRA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| KLRA | Kailera Therapeutics, Inc.(you) | $2.1B | 11 | Strong Sell |
| COAG | Hemab Therapeutics Holdings, Inc. | $2.1B | 11 | Strong Sell |
| STOK | Stoke Therapeutics, Inc. | $2.0B | 13 | Strong Sell |
| BRVE | Braveheart Bio, Inc. | $1.9B | 11 | Strong Sell |
| KOD | Kodiak Sciences Inc. | $2.4B | 12 | Strong Sell |
| KARD | Kardigan, Inc. | $1.9B | 11 | Strong Sell |
| INBX | Inhibrx Biosciences, Inc. | $1.8B | 13 | Strong Sell |
| ZBIO | Zenas BioPharma, Inc. | $2.0B | 15 | Strong Sell |
| RXRX | Recursion Pharmaceuticals, Inc. | $1.8B | 12 | Strong Sell |
| MLYS | Mineralys Therapeutics, Inc. | $2.3B | 14 | Strong Sell |
Peer medians: ROE -30.7% · P/E 27.0x · Gross margin 58.3%